Open access · OA
via OpenAlex
mTOR Modulates NLRP3 Inflammasome Activation via Nuclear Translocation and STAT1 Inhibition
Álvaro González‐Domínguez, Shuling Zhang, Daniel Boy‐Ruiz, Daniel Connors, Raquel de la Varga‐Martínez, Beverly A. Mock, Mario David Cordero
European Journal of Immunology · 2025 · ▲ 6 citations
Abstract
The NLRP3 inflammasome has emerged as an unexpected sensor of metabolic danger and stress. Their enhanced activation has been implicated in the development of major diseases such as gout, Type 2 diabetes, obesity, cancer, and neurodegenerative and cardiovascular diseases. In this study, we showed that mammalian target of mTOR(definition)-inhibiting drug studied for extending healthspan and lifespan." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">rapamycin(definition) (mTOR) regulates NLRP3 inflammasome activation in the nucleus of macrophages. mTOR binds to NLRP3 under basal conditions, and this binding is reduced after lipopolysaccharides (LPS) or LPS + adenosine triphosphate (ATP) treatment. Furthermore, rapamycin-induced downregulation of mTOR expression has an inhibitory effect on NLRP3 inflammasome activation. mTOR knockdown (KD) mice exhibit reduced protein levels of inflammasome components, and their macrophages fail to activate the NLRP3 inflammasome after LPS + ATP treatment. From a mechanistic point of view, LPS + ATP treatment induced the nuclear translocation of mTOR, leading to enhanced NLRP3 inflammasome activation. However, the mTOR inhibition by rapamycin treatment increased phosphorylation of STAT1 which repressed NLRP3 activation. When rapamycin was combined with the STAT1 inhibitor fludarabine, NLRP3 inflammasome activity was restored. Taken together, these findings suggest a role for mTOR in NLRP3 regulation and identify a potential therapeutic option for controlling inflammasome activation.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1002/eji.202451176
- Canonical
- link ↗
- Fetched
- 2026-11-14 MST
Cite this
APA
González‐Domínguez, �., Zhang, S., Boy‐Ruiz, D., Connors, D., Varga‐Martínez, R.D.L., Mock, B.A., & Cordero, M.D. (2025). mTOR Modulates NLRP3 Inflammasome Activation via Nuclear Translocation and STAT1 Inhibition. <em>European Journal of Immunology</em>. https://doi.org/10.1002/eji.202451176
Vancouver
González‐Domínguez �, Zhang S, Boy‐Ruiz D, Connors D, Varga‐Martínez RDL, Mock BA, et al. mTOR Modulates NLRP3 Inflammasome Activation via Nuclear Translocation and STAT1 Inhibition. European Journal of Immunology. 2025. doi:10.1002/eji.202451176.
BibTeX
@article{lvaro2025mTORMo,
title = {mTOR Modulates NLRP3 Inflammasome Activation via Nuclear Translocation and STAT1 Inhibition},
author = {Álvaro González‐Domínguez and Shuling Zhang and Daniel Boy‐Ruiz and Daniel Connors and Raquel de la Varga‐Martínez and Beverly A. Mock and Mario David Cordero},
journal = {European Journal of Immunology},
year = {2025},
doi = {10.1002/eji.202451176},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Human Biology 2014
Open access · OA
Effect Of Folate Deficiency On Expression Of Proteins On The Mtor Signaling Pathway In The Brain Of C57/bl6 Mice
Aging Pathobiology and Therapeutics 2026
Open access · CC-BY
mTOR signaling in aging and longevity: therapeutic opportunities
AMS Dottorato Institutional Doctoral Theses Repository (University of Bologna) 2013
Preprint · OA
adaptive capabilities of the pi3k/akt/mtor pathway in acute myeloid leukemia revealed by the use of selective inhibitors
Frontiers in Neuroscience 2019
Open access · CC-BY
Insulin and Autophagy in Neurodegeneration
Frontiers in Endocrinology 2018
Open access · CC-BY
mTORC1 Overactivation as a Key Aging Factor in the Progression to Type 2 Diabetes Mellitus
Oxidative Medicine and Cellular Longevity 2018
Open access · CC-BY